Concepts (131)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Anaphylaxis | 4 | 2021 | 940 | 0.92 | Why? |
| Adverse Drug Reaction Reporting Systems | 11 | 2021 | 694 | 0.69 | Why? |
| Chickenpox Vaccine | 1 | 2017 | 59 | 0.63 | Why? |
| Syphilis | 2 | 2018 | 318 | 0.50 | Why? |
| Treponema pallidum | 1 | 2013 | 42 | 0.50 | Why? |
| Product Surveillance, Postmarketing | 3 | 2021 | 189 | 0.50 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 2 | 2021 | 1261 | 0.46 | Why? |
| HIV | 1 | 2018 | 1116 | 0.43 | Why? |
| Immunization, Secondary | 1 | 2017 | 1649 | 0.37 | Why? |
| Herpes Zoster Vaccine | 2 | 2019 | 112 | 0.33 | Why? |
| Herpesvirus 3, Human | 2 | 2018 | 228 | 0.31 | Why? |
| Vaccines, Attenuated | 3 | 2018 | 952 | 0.26 | Why? |
| Herpes Zoster | 2 | 2018 | 331 | 0.23 | Why? |
| Immunization | 2 | 2021 | 2019 | 0.23 | Why? |
| Epidermolysis Bullosa | 1 | 2020 | 60 | 0.20 | Why? |
| Drug Approval | 4 | 2021 | 1325 | 0.19 | Why? |
| Guanylate Cyclase | 1 | 2018 | 10 | 0.19 | Why? |
| Skin Diseases, Papulosquamous | 1 | 2018 | 19 | 0.18 | Why? |
| Lipoxins | 1 | 2018 | 64 | 0.18 | Why? |
| Sinus Thrombosis, Intracranial | 2 | 2021 | 550 | 0.18 | Why? |
| Syncope | 1 | 2021 | 238 | 0.18 | Why? |
| CARD Signaling Adaptor Proteins | 1 | 2018 | 70 | 0.18 | Why? |
| Neoplastic Syndromes, Hereditary | 1 | 2017 | 14 | 0.17 | Why? |
| Thrombocytopenia | 2 | 2021 | 2093 | 0.17 | Why? |
| Hemangioma, Capillary | 1 | 2017 | 17 | 0.17 | Why? |
| Meningitis, Aseptic | 1 | 2017 | 22 | 0.17 | Why? |
| Propranolol | 1 | 2017 | 36 | 0.17 | Why? |
| United States | 14 | 2021 | 46150 | 0.16 | Why? |
| Viral Vaccines | 1 | 2018 | 7560 | 0.16 | Why? |
| Dry Eye Syndromes | 1 | 2018 | 113 | 0.16 | Why? |
| Vaccines, Synthetic | 4 | 2021 | 3231 | 0.15 | Why? |
| Ustekinumab | 1 | 2018 | 216 | 0.15 | Why? |
| Vaccines, Conjugate | 1 | 2018 | 328 | 0.15 | Why? |
| Cellulitis | 1 | 2017 | 119 | 0.15 | Why? |
| Rhinitis, Allergic, Seasonal | 1 | 2017 | 121 | 0.15 | Why? |
| Meningitis, Viral | 1 | 2017 | 97 | 0.15 | Why? |
| HIV Infections | 2 | 2018 | 11620 | 0.15 | Why? |
| Infectious Disease Transmission, Vertical | 1 | 2013 | 5164 | 0.15 | Why? |
| Measles-Mumps-Rubella Vaccine | 1 | 2018 | 282 | 0.14 | Why? |
| Vaccination | 3 | 2021 | 19050 | 0.14 | Why? |
| Facial Dermatoses | 1 | 2018 | 222 | 0.14 | Why? |
| Eye | 1 | 2018 | 374 | 0.13 | Why? |
| Consensus | 2 | 2020 | 6345 | 0.13 | Why? |
| Vasodilator Agents | 1 | 2017 | 344 | 0.13 | Why? |
| Practice Guidelines as Topic | 4 | 2021 | 15421 | 0.13 | Why? |
| Syphilis Serodiagnosis | 1 | 2013 | 30 | 0.13 | Why? |
| Chickenpox | 1 | 2017 | 194 | 0.13 | Why? |
| Eczema | 1 | 2017 | 227 | 0.13 | Why? |
| Safety | 1 | 2021 | 1583 | 0.13 | Why? |
| T-Lymphocytes, Regulatory | 1 | 2018 | 698 | 0.12 | Why? |
| Vomiting | 1 | 2017 | 722 | 0.11 | Why? |
| Dermatologic Agents | 1 | 2018 | 489 | 0.11 | Why? |
| Safety-Based Drug Withdrawals | 2 | 2021 | 52 | 0.11 | Why? |
| Lymph Nodes | 1 | 2018 | 1060 | 0.11 | Why? |
| Mass Vaccination | 1 | 2021 | 1101 | 0.11 | Why? |
| Headache | 2 | 2021 | 2257 | 0.10 | Why? |
| Advisory Committees | 3 | 2021 | 1418 | 0.10 | Why? |
| Adolescent | 11 | 2021 | 86841 | 0.10 | Why? |
| Encephalitis | 1 | 2017 | 797 | 0.10 | Why? |
| Myocarditis | 2 | 2021 | 2731 | 0.09 | Why? |
| Infant | 5 | 2021 | 30274 | 0.09 | Why? |
| Child, Preschool | 5 | 2021 | 36283 | 0.09 | Why? |
| Stillbirth | 1 | 2013 | 544 | 0.09 | Why? |
| Female | 17 | 2021 | 380317 | 0.08 | Why? |
| Membrane Proteins | 1 | 2018 | 1733 | 0.08 | Why? |
| Male | 16 | 2021 | 367725 | 0.08 | Why? |
| Pregnancy Complications, Infectious | 1 | 2013 | 11559 | 0.08 | Why? |
| Adult | 12 | 2021 | 244371 | 0.08 | Why? |
| Child | 7 | 2021 | 70012 | 0.08 | Why? |
| Patient Care Team | 1 | 2020 | 3556 | 0.08 | Why? |
| Diet | 1 | 2018 | 2052 | 0.07 | Why? |
| Age of Onset | 2 | 2018 | 557 | 0.07 | Why? |
| Sentinel Surveillance | 1 | 2013 | 1093 | 0.07 | Why? |
| Middle Aged | 11 | 2021 | 270681 | 0.07 | Why? |
| United States Food and Drug Administration | 2 | 2021 | 1276 | 0.06 | Why? |
| Humans | 22 | 2021 | 930598 | 0.06 | Why? |
| Infant, Newborn | 4 | 2021 | 23105 | 0.06 | Why? |
| Young Adult | 7 | 2021 | 93724 | 0.06 | Why? |
| Vaccines | 1 | 2021 | 3692 | 0.06 | Why? |
| Neutrophils | 1 | 2018 | 5476 | 0.06 | Why? |
| Drug Labeling | 1 | 2021 | 65 | 0.05 | Why? |
| Aged, 80 and over | 6 | 2021 | 88759 | 0.05 | Why? |
| Fever | 1 | 2017 | 7795 | 0.05 | Why? |
| Thrombosis | 1 | 2021 | 7504 | 0.05 | Why? |
| Asthma | 1 | 2017 | 4383 | 0.04 | Why? |
| Pityriasis Rubra Pilaris | 1 | 2018 | 26 | 0.04 | Why? |
| Retreatment | 1 | 2018 | 186 | 0.04 | Why? |
| Injection Site Reaction | 1 | 2018 | 124 | 0.04 | Why? |
| Docosahexaenoic Acids | 1 | 2018 | 145 | 0.04 | Why? |
| Algorithms | 1 | 2013 | 7346 | 0.04 | Why? |
| Anxiety | 1 | 2021 | 17311 | 0.04 | Why? |
| Platelet Count | 1 | 2021 | 1381 | 0.04 | Why? |
| Pregnancy | 2 | 2018 | 23879 | 0.04 | Why? |
| Genetic Testing | 1 | 2018 | 395 | 0.03 | Why? |
| Aged | 6 | 2021 | 215776 | 0.03 | Why? |
| Drug Eruptions | 1 | 2018 | 319 | 0.03 | Why? |
| Sexual Partners | 1 | 2018 | 612 | 0.03 | Why? |
| Mass Screening | 1 | 2013 | 8005 | 0.03 | Why? |
| Risk Assessment | 3 | 2021 | 25439 | 0.03 | Why? |
| Cluster Analysis | 1 | 2021 | 3001 | 0.03 | Why? |
| Interdisciplinary Communication | 1 | 2020 | 1425 | 0.03 | Why? |
| Fatal Outcome | 1 | 2021 | 3438 | 0.03 | Why? |
| Hospitalization | 1 | 2021 | 54280 | 0.02 | Why? |
| Homosexuality, Male | 1 | 2018 | 1158 | 0.02 | Why? |
| Sexual Behavior | 1 | 2018 | 1322 | 0.02 | Why? |
| Drug Monitoring | 1 | 2017 | 1408 | 0.02 | Why? |
| Sexual and Gender Minorities | 1 | 2018 | 1019 | 0.02 | Why? |
| Mice, Inbred C57BL | 1 | 2018 | 5542 | 0.02 | Why? |
| Cells, Cultured | 1 | 2018 | 5835 | 0.02 | Why? |
| Phenotype | 1 | 2018 | 4037 | 0.02 | Why? |
| Risk | 1 | 2017 | 5288 | 0.02 | Why? |
| Cause of Death | 1 | 2018 | 4823 | 0.02 | Why? |
| Psoriasis | 1 | 2018 | 1739 | 0.02 | Why? |
| Australia | 1 | 2017 | 6306 | 0.02 | Why? |
| Patient Selection | 1 | 2017 | 4560 | 0.01 | Why? |
| Retrospective Studies | 1 | 2013 | 105322 | 0.01 | Why? |
| Incidence | 1 | 2021 | 25622 | 0.01 | Why? |
| Mice | 1 | 2018 | 21357 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2017 | 17020 | 0.01 | Why? |
| Coinfection | 1 | 2018 | 6820 | 0.01 | Why? |
| Disease Progression | 1 | 2017 | 13580 | 0.01 | Why? |
| Critical Care | 1 | 2021 | 14081 | 0.01 | Why? |
| Age Factors | 1 | 2018 | 21039 | 0.01 | Why? |
| Prevalence | 1 | 2018 | 25773 | 0.01 | Why? |
| Betacoronavirus | 1 | 2020 | 204454 | 0.01 | Why? |
| Cohort Studies | 1 | 2017 | 36005 | 0.01 | Why? |
| Pandemics | 1 | 2020 | 389249 | 0.01 | Why? |
| Pneumonia, Viral | 1 | 2020 | 243684 | 0.01 | Why? |
| Coronavirus Infections | 1 | 2020 | 253789 | 0.01 | Why? |
| Risk Factors | 1 | 2018 | 71621 | 0.01 | Why? |
| Animals | 1 | 2018 | 78931 | 0.01 | Why? |
Su's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(131)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(124)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_